Biosergen publishes 2024 annual report

April 30, 2025: Biosergen AB (“Biosergen” or the “Company”) hereby announces that the 2024 annual report is available on the company website www.biosergen.net (https://www.biosergen.net/investor-relations#Financial%20Reports)

For further information about Biosergen, please contact:

Tine Olesen, CEO
Telefon: +45 3135 5707
E-mail: tine.olesen@biosergen.net

Niels Laursen, CFO
Telephone: +45 4014 5059
E-mail: niels.laursen@biosergen.net

Bolagets Certified Adviser är Carnegie Investment Bank AB (publ).

ABOUT BIOSERGEN
Biosergen is a clinical stage biotechnology company advancing the treatment of life-threatening fungal infections. Biosergen’ s mission is to develop the drug candidate BSG005 into a superior antifungal therapy with broader efficacy and improved safety over existing treatments. Unlike conventional options, BSG005 potential is to eliminate fungal infections rather than just slowing their growth, reducing the risk of resistance. Consequently, BSG005 is set to become a new first line treatment choice for resistant and/or difficult to treat invasive fungal infections, offering a safer and more effective solution where current therapies fall short ultimately saving thousands of lives of lives of immune-compromised cancer, transplant and AIDS patients every year.